Bicara Therapeutics Inc. Overview
Pro stress-test →Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody combining an EGFR-directed monoclonal antibody with a TGF-beta-binding domain for treating solid tumors. The company recently went public in September 2024 and is advancing its pipeline toward pivotal trials.
Strategic Profile
Pro stress-test →Bicara's development strategy centers on ficerafusp alfa for solid tumors. Key clinical focus areas include FORTIFI-HN01 (a Phase 2/3 trial in head and neck cancer) with enrollment expected to support an interim analysis in mid-2027 for potential accelerated filing, plus expansion cohorts in colorectal cancer. The dual-targeting approach addresses both tumor-intrinsic and immune-suppressive mechanisms in hard-to-treat cancers.
Competitive Landscape
Pro stress-test →Bicara competes in the oncology biopharmaceutical space against larger companies developing immune-oncology and targeted therapies. Key competitors include established players like Merck (Keytruda), Bristol Myers Squibb, and Regeneron in checkpoint inhibition, as well as emerging biotech focused on combination approaches. Bicara's bifunctional platform differentiates through dual EGFR/TGF-beta targeting rather than single-mechanism approaches.
Industry Context
Bicara Therapeutics Inc. operates in Biopharmaceutical - Oncology (Solid Tumors).
Key facts
Founded: 2018 · Headquarters: Boston, Massachusetts · Revenue: $0 · Market cap: $919M